Skip Main Navigation
Page Content
This event has ended

Save This Event

Event Saved

2012 UCL Prize Lecture in Clinical Science

SLMS Communications Manager

Tuesday, 2 October 2012 at 17:30

Ticket Information

Type End Quantity
UCL Prize Lecture in Clinical Science Ended Free  

Event Details

Professor Jeffrey M. Friedman
Marilyn M. Simpson Professor and Head of Laboratory of Molecular Genetics, The Rockefeller University

‘To Eat or Not to Eat: Leptin and the Biologic Basis of Obesity’

This annual prize lecture series has been running for 16 years but within this short space of time has rapidly become the pre-eminent series on contemporary science in Europe.  The whole event, which provides an opportunity to debate and celebrate important scientific advancements, has always been very stimulating and hugely enjoyable.

This year the Prize Lecture will be given by Professor Jeffrey M. Friedman. Prior to Jeffrey M. Friedman's groundbreaking research, little was known about the components of the biologic system that controls weight, and many scientists questioned the very existence of such a system. Dr. Friedman's 1994 identification of the weight- and appetite-regulating hormone leptin, however, provided a genetic explanation of obesity and has challenged the popular belief that lack of willpower causes people to be obese. For his discovery of leptin, which ultimately opened obesity research to molecular exploration, Dr. Friedman was awarded the 2010 Albert Lasker Basic Medical Research Award.

5.25pm for 5.30pm

Professor Jeffrey M. Friedman
‘To Eat or Not to Eat: Leptin and the Biologic Basis of Obesity’

Cruciform Building, Lecture Theatre 1, Gower Street, WC1E 6BT 

Following the lecture there will be a reception in the North Cloisters, UCL Main Campus.

Booking details
You can only book one ticket per person. To book, please click the "Register" button above and follow the online instructions.  Once your registration is complete you will be sent a booking confirmation email, please bring a copy of this with you, no further tickets will be sent through the post. Places are available on a first come, first serve basis.

Contact details
For further information please contact Morgan Williams, UCL Communications Manager at or telephone 020 7679 6944 Please note this event will be filmed

WATCH video of last year's event


Dr. Friedman graduated from Rensselaer Polytechnic Institute and, in 1977 at the age of 22, received his M.D. from Albany Medical College of Union University. After completing two residencies at Albany Medical Center Hospital, Dr. Friedman came to Rockefeller as a postgraduate fellow and associate physician in 1980. In 1986 he received his Ph.D., working in the lab of James E. Darnell Jr., and was appointed assistant professor. In 1991 he was named head of laboratory, and in 1995 he was promoted to professor. He was appointed the Marilyn M. Simpson Professor in 1999. He has been an investigator at the Howard Hughes Medical Institute since 1986, and he directs the university's Starr Center for Human Genetics.

In December 1994, Dr. Friedman and his colleagues published a landmark paper in the journal Nature, in which they identified a gene in mice and humans called obese (ob) that codes for a hormone he later named leptin, after the Greek word leptos, for thin. Dr. Friedman and colleagues showed that leptin is a hormonal signal made by the body's fat cells that regulates food intake and energy expenditure. Leptin has powerful effects on reproduction, metabolism, other endocrine systems and even immune function.

Mice that lack ob, and thus do not produce leptin, are massively obese, weighing as much as three times more than their normal littermates. Dr. Friedman showed that after normal and ob-deficient mice are injected with synthetic leptin, they are more active and lose weight.

In humans, the lack of leptin has been linked to overeating, with people who do not produce enough leptin often eating copious amounts and becoming massively obese. Dr. Friedman has treated some leptin-deficient obese individuals with leptin, and has shown it can lead to massive weight loss. The dramatic effect of leptin in these patients has established a key role for this hormone in human physiology.

However, the majority of obese people have very high levels of leptin circulating in their blood. Dr. Friedman's lab went on to show that high leptin levels are often associated with resistance to leptin, and they uncovered evidence which suggests that animals destined to be obese increase their production of leptin to satisfy a higher set point for weight. These observations have reframed views on the pathogenesis of obesity and suggested that the development of approaches to improve leptin response in resistant individuals could provide new treatments for obesity.

With the discovery of leptin and Friedman's subsequent studies, the logic of an entirely new physiological system has been established with direct implications for the pathophysiology of human obesity. In addition to providing scientists with a new target for treating obesity, the discovery has helped scientists develop treatments for other metabolic conditions, such as diabetes, and for women with hypothalamic amenorrhea.

A member of the National Academy of Sciences and its Institute of Medicine, Dr. Friedman's previous honors include the 2009 Shaw Prize in Life Science and Medicine, 14th annual Keio Medical Science Prize, the 2007 Jessie Stevenson Kovalenko Medal, the sixth Danone International Prize for Nutrition, the 2004 Gairdner Foundation International Award and the 2004 Passano Foundation Award.

Do you have questions about 2012 UCL Prize Lecture in Clinical Science? Contact SLMS Communications Manager

When & Where

Cruciform Building
Lecture Theatre 1
Gower Street
WC1E 6BT London
United Kingdom

Tuesday, 2 October 2012 at 17:30

  Add to my calendar


Interested in hosting your own event?

Join millions of people on Eventbrite.

Please log in or sign up

In order to purchase these tickets in installments, you'll need an Eventbrite account. Log in or sign up for a free account to continue.